Beam’s base-edited sickle cell therapy meets its pivotal endpoint

On November 10, Beam Therapeutics reported that risto-cel met the primary efficacy endpoint in a prespecified interim analysis of the Phase 1/2 BEACON trial. Independent adjudicators assessed whether patients went at least 12 consecutive months without a severe vaso-occlusive crisis, when sickled blood cells obstruct circulation. Of 49 people treated, 31 had completed the follow-up required for that endpoint at the October 20 cutoff. Beam did not disclose the response rate.

Risto-cel uses a patient’s own blood-forming stem cells. Base editing changes targeted DNA letters to increase production of fetal hemoglobin, which can reduce sickling. Measuring severe crises connects that molecular strategy to an outcome that matters directly to patients. Beam expects to file for U.S. approval as early as year-end.

BEACON is an open-label, single-arm trial. Detailed pivotal results are planned for 2027. The treatment requires intensive conditioning with busulfan before the edited cells are infused, so the full safety and durability data will matter alongside the efficacy result.